Amphotec And Aspergillosis
Amphotec (amphotericin B colloidal dispersion) is more effective and less toxic than amphotericin B in the treatment of potentially fatal aspergillosis and other major fungal infections, according to results from a retrospective study on 343 patients. The data were presented at the International Conference of Infectious Diseases in Hong Kong on June 13.
This reinforces data demonstrated by Mary White of the Memorial Sloan-Kettering Cancer Center in New York City, which showed Amphotec to have greater efficacy (43%) in 82 patients compared to amphotericin B (23%) in 261 patients. Amphotec also offered a 50% survival rate at 120 days as opposed to a 28% survival rate with amphotericin B. Side effects of nephrotoxicity were also greatly reduced.
Sequus Pharmaceuticals, which is developing Amphotec (also known as Amphocil outside the USA), has filed a New Drug Application for the product with the US Food and Drug Administration. It is currently approved for use in 10 countries.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze